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Abstract
Background: Influenza epidemics continue to cause morbidity and mortality within the human
population despite widespread vaccination efforts. This, along with the ominous threat of an avian
influenza pandemic (H5N1), demonstrates the need for a much improved, more sophisticated
influenza vaccine. We have developed an in vitro model system for producing a membrane-bound
Cytokine-bearing Influenza Vaccine (CYT-IVAC). Numerous cytokines are involved in directing
both innate and adaptive immunity and it is our goal to utilize the properties of individual cytokines
and other immunomodulatory proteins to create a more immunogenic vaccine.
Results: We have evaluated the immunogenicity of inactivated cytokine-bearing influenza vaccines
using a mouse model of lethal influenza virus challenge. CYT-IVACs were produced by stably
transfecting MDCK cell lines with mouse-derived cytokines (GM-CSF, IL-2 and IL-4) fused to the
membrane-anchoring domain of the viral hemagglutinin. Influenza virus replication in these cell lines
resulted in the uptake of the bioactive membrane-bound cytokines during virus budding and
release. In vivo efficacy studies revealed that a single low dose of IL-2 or IL-4-bearing CYT-IVAC is
superior at providing protection against lethal influenza challenge in a mouse model and provides a
more balanced Th1/Th2 humoral immune response, similar to live virus infections.
Conclusion: We have validated the protective efficacy of CYT-IVACs in a mammalian model of
influenza virus infection. This technology has broad applications in current influenza virus vaccine
development and may prove particularly useful in boosting immune responses in the elderly, where
current vaccines are minimally effective.

Background
Influenza epidemics continue to cause morbidity and
mortality within the human population. Yearly epidemics
affect 5–20% of the population leading to over 200,000
hospitalizations and up to 36,000 deaths annually in the

United States [1]. The economic impact of influenza
related illness costs the United States upwards of $167 billion dollars per year [1]. The recent emergence of highly
pathogenic avian influenza (HPAI) H5N1 has significantly raised awareness and concern of a pending panPage 1 of 17
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demic flu event. Prior to 1997, it was thought that HPAI
circulating in avian species could not be directly transmitted to humans. However, recent studies have documented
that HPAI can cross the avian-human species barrier and
infect humans, leading to disease and high mortality
(50%) [2-4]. Furthermore, recent incidences of low-grade
human-to-human transmission of H5N1 have heightened
concerns that an H5N1 pandemic may occur [5]. Continual yearly outbreaks of influenza and the looming threat
of a potential influenza pandemic illustrate the growing
need for improved influenza vaccines.
The ability of adjuvants to enhance vaccine efficacy have
been well documented, yet the current commercially
available influenza vaccines in the United States do not
utilize any licensed form of adjuvant. Oil adjuvants, such
as incomplete Freund's adjuvant, have long been known
to boost the immune response to co-administered antigens; however these oil-based adjuvants are not ideal
adjuvant candidates due to potential side effects [6].
Recent studies have begun to look at other methods of
boosting the immune response to influenza antigens
using adjuvants such as alum, MF59, and Quil A, as well
as Influenza-Immunostimulating Complex (ISCOM), an
immune complex comprised of influenza antigen, cholesterol, lipid, and saponins [7-10].
Immunomodulatory proteins such as cytokines and
chemokines have been evaluated for their ability to augment vaccine immunogenicity in numerous vaccine candidates. Cytokines and chemokines such as RANTES, IL12, IL-6, and GM-CSF, delivered as either soluble protein
or plasmid expression vector, have proven to boost the
immune responses to co-administered antigens [11-13].
While the adjuvant potential of cytokines and chemokines are clearly demonstrated in these studies, two major
problems arise for those vaccines using soluble forms of
cytokines and chemokines, (1) dispersion of the protein
from the site of administration and (2) the short half-life
of the protein. It has been suggested that immunomodulators may function better if they are maintained in close
proximity or juxtaposed to antigens and remain in their
bioactive state for a longer period of time [14-17].
Recently, encapsulation or fusion of immunomodulators
(GM-CSF, IL-2) directly to the cognate antigen has been
shown to significantly augment immune responses [1821]. Clearly, presentation of immunomodulators in close
association with antigen greatly increases the immunogenicity of the antigen.
As a means to boost the immunogenicity of whole virus
vaccines or even subunit vaccines, we postulated that inactivated virus particles bearing membrane-bound immunostimmulatory molecules would elicit a more robust
and balanced humoral immune response to influenza
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virus. Here, we describe studies demonstrating the ability
of CYT-IVACs (cytokine bearing influenza virus vaccines)
to boost antiviral humoral immune responses and protect
against lethal challenge using a mouse model of infection.

Methods
Construction of expression plasmids
Mouse-derived granulocyte macrophage-colony stimulating factor (mGM-CSF) and interleukin 2 and 4 (mIL-2,
mIL-4) were fused to a short stalk, transmembrane, and
cytoplasmic tail domain of influenza A/WSN/33 hemagglutinin (HA) using standard PCR methodologies as
described previously [22]. Briefly, primers, amplifying the
carboxyl terminal 71 amino acids of WSN HA and the
coding sequence of the cytokines, were designed to introduce the appropriate restriction sites. Nucleotides 1521–
1730 coding for the 26 amino acid stalk region, the transmembrane domain, and cytoplasmic tail domain of the
hemagglutinin were amplified using the forward primer
5'-CCGGATCCAATGGGACTTATGATTATCC-3' and the
reverse
primer
5'-CCGAATTCTCAGATGCATATTCTGCACTGC-3' to introduce restriction sites Bam HI and
Eco RI (underlined), respectively. Primers specific for
mGM-CSF (forward 5'-CCAAGCTTGGAGGATGTGGCTGCAGAA-3'; reverse 5'-GGGGATCCTTTTTGGACTGGTTT
TTTGC-3'), mIL-2 (forward 5'-CCGGTACCAGCATGCAGCTCGCATCCTGTGTC-3'; reverse 5'-GGGGATCCTTGAGGGCTTGTTGAGATGA-3'), and mIL-4 (forward
5'-CCGGTACCGCACCATGGGTCTCAACCCCCA-3';
reverse 5'-CCGGATCCCGAGTAATCCATTTGCATGATG3') were designed to remove stop codons and introduce
Hind III (mGM-CSF) or Kpn I (mIL-2 and mIL-4) and
BamHI endonuclease restriction sites on the 5' and 3' ends
respectively. PCR products were generated using Platinum
Pfx (Invitrogen) and GeneAmp PCR System 2400
(Applied Biosystems). Purified PCR products were subsequently digested and inserted into the respective restriction sites of pcDNA3.1 using T4 DNA Ligase (Invitrogen)
according to the manufacturers protocol. Plasmid constructs, harboring the respective fusion constructs, were
sequenced by the Wayne State University Sequencing
Core (Applied Genomics Technology Center) to verify
sequence and integrity of the constructs.
Generation of CYT-IVAC producer cell lines
Madin-Darby canine kidney (MDCK) cells were maintained in complete growth media (DMEM/10% FBS) consisting of Dulbecco's Modified Eagles Media
supplemented with 10% fetal bovine serum (Atlanta Biologicals) and the antibiotics penicillin/streptomycin (100
U/100 μg). Cells were transfected with expression plasmids using Lipofectamine2000 (Invitrogen) as described
previously [22]. Stable transfectants were selected by
growth in DMEM/10%FBS supplemented with Geneticin
(1.5 mg/ml; Gibco). Geneticin-resistant cells were sub-
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cloned by limiting dilution plating in 96-well plates in the
presence of Geneticin (G418™ Invitrogen, 1 mg/ml). Individual MDCK subclones were screened for cell surface
expression and bioactivity of the respective membranebound cytokines.
Viral infection, purification, and inactivation
Wild-type and CYT-IVAC producer MDCK cells (90% confluent) were infected at an MOI of 1 with either influenza
virus A/PR/8/34 (H1N1) or A/Udorn/72 (H3N2). Following virus adsorption (1 hr, 37°C), the inoculum was
removed and DMEM/2% FBS was added. Supernatants
from infected monolayers were harvested 24–36 hours
post infection and cellular debris was pre-cleared at 400 ×
g for 15 minutes at 4°C. Virions were purified by centrifugation through two sequential 10–26% iodixanol continuous gradients (OptiPrep™, Axis-Schield) (SW41 rotor,
55,000 × g, 45 min at 4°C). Banded virus was collected
and concentrated by centrifugation at 88,000 × g for 45
minutes at 4°C and subsequently re-suspended in phosphate-buffered saline, PBS. Purified virus was inactivated
by treatment with 15 mM β-propiolactone for 15 minutes
at 25°C. The reaction was neutralized by the addition of
sodium thiosulfate (40 mM final concentration, 30 min,
25°C). Inactivated virus was diluted with PBS, pelleted by
centrifugation as described and resuspended in sterile
PBS. Total viral protein concentration was determined
using a bicinchoninic acid protein assay kit (Pierce Biotechnology). Inactivation was confirmed by monitoring
cytopathic effect in MDCK cells treated with 5 μg of inactivated virus vaccine for a period of 3–5 days at 37°C in
the presence of 1.5 μg/ml TPCK-treated trypsin (Sigma).
Cell surface expression and viral incorporation of
membrane-bound cytokines (Immunofluorescence
Microscopy)
MDCK cells were grown to 90% confluency on glass cover
slips in 24 well plates. Cells were washed with phosphate
buffered saline (PBS) and fixed with 3% paraformaldehyde (PF) in 250 mM HEPES for 10 minutes at room temperature (RT). PF was removed and 50 mM glycine in PBS
was added for 10 minutes at RT to quench any remaining
PF. Cells were washed 2 times with PBS and blocked with
2% chicken serum in PBS for 30 minutes at RT. For immunostaining cells were incubated sequentially with rat anticytokine specific antibody (BD Pharmagen) and chicken
anti-rat IgG conjugated Alexa Fluor® 488 antibody (Invitrogen/Molecular Probes). All antibodies were diluted in
PBS/2% chicken serum. Cover slips were mounted on
slides using ProLong Antifade (Invitrogen/Molecular
Probes). Immunofluorescent staining was visualized
using a Nikon E800 Epifluorescence Microscope. Digital
images were captured using a Roper CoolSnap FX digital
camera and analyzed using MetaMorph Imaging Software
(Universal Imaging).
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To visualize viral incorporation of membrane-bound
cytokines, CYT-IVAC producer cells, grown on cover slips,
were infected with filamentous influenza A/Udorn/72 at
an MOI of 1. The cells were fixed at 8 hr post-infection
with 3% PF and blocked as described above. Cells were
incubated with rat anti-cytokine specific primary antibody
and Alexa Fluor® 488 conjugated secondary antibody as
described above. Additionally, cells were incubated with
goat anti-H3 antibody and secondary chicken Alexa Fluor®
594 conjugated anti-goat IgG (Invitrogen/Molecular
Probes). Cover slips were mounted and immunofluorescence was analyzed as described above.
Western blot analysis
Vaccines were solubilized in Laemmli Buffer (BioRad)
(LB) and heated at 96°C for 10 minutes to denature proteins. Samples were separated on 12% PAGE-SDS and
subsequently blotted to PVDF membrane. Membranes
were probed by sequential incubation with rat anti-GMCSF (BD Bioscience), followed by goat anti-rat IgG horseradish-peroxidase conjugated secondary antibody (Santa
Cruz). Membranes were exposed to ECL or Femto solution per manufacturers (Pierce) instructions and membranes were visualized using Chemdoc XRS (BioRad).
Total Cytokine and Hemagglutinin Quantitation by Slot
Blot Assay
Serial dilutions of vaccines at 1, 0.5 and 0.25 μg (cytokine
quantification) or 1, 0.2 and 0.04 μg (HA quantification)
of total viral protein, as well as serial diluted recombinant
cytokine (2000 ng to 1.95 ng) were blotted on PVDF
membranes using a slot blot apparatus. Membranes were
blocked with 5% milk solution and subsequently incubated sequentially with diluted primary antibody, specific
for the respective cytokine (rat anti-GM-CSF, IL-2, or IL-4,
BD Bioscience) or hemagglutinin (mouse anti-HA, Meridian Life Science® Inc or rabbit anti-H1N1/Pan H1, Pierce®
Inc) followed by the respective horseradish-peroxidase
conjugated secondary antibody (goat anti-rat IgG (Santa
Cruz), goat anti-mouse IgG (BioRad) or goat anti-rabbit
IgG (Sigma). Membranes were exposed to ECL or Femto
solution per manufacturers (Pierce®) instructions and
chemiluminescent signals were recorded using a Chemdoc XRS (BioRad). Images were processed with ImageJ
software (NIH freeware) and standard curves for each
cytokine were generated using optical pixel densities.
Total cytokine content for each vaccine preparation was
extrapolated from standard curves and is expressed as the
average of the three dilutions evaluated for each vaccine in
nanograms (ng) of cytokine per microgram (μg) of total
viral protein. The signal intensity of the HA specific signal
for each vaccine was calculated for each dilution and the
average pixel density per μg of total viral protein is given.
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Hemagglutination Assay
Hemagglutination units (HAU) were determined by
agglutination of chicken red blood cells as previously
described [23]. Briefly, serial diluted vaccine preparations
were mixed with an equal volume of fresh 0.5% chicken
red blood cells and incubated at room temperature for 30
minutes. Red blood cell agglutination was recorded and
HAU per μg of total viral protein is expressed as the reciprocal of the last dilution of virus that resulted in agglutination.
Bioassays of membrane-bound cytokines
Bone marrow (BM) cells, as indicator cells for mGM-CSF
bioactivity, were prepared from the femurs of female
Balb/c mice. Briefly, bone marrow was flushed from the
femurs with RPMI and the cell suspension passed through
a 70 μm cell strainer. Red blood cells were lysed using RBC
lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.01%
EDTA). Cells were washed 2 times with RPMI and re-suspended in complete RPMI (10% FBS, 20 mM L-glutamine,
1 M HEPES, 100 mM Sodium Pyruvate, 55 μM 2β-Mercaptoethanol, Penicillin/Streptomycin (100 units/100 μg/
ml)). For MDCK based bioassays, BM cells (2 × 105/well)
were added to wells of a 96 well plate containing 90%
confluent, mitomycin C (50 μg/ml) treated wild type or
CYT-IVAC producer (mGM-CSF~HA) MDCK cells. For
virus based bioassays and quantitation of viral incorporated bioactive GM-CSF, BM cells (2 × 105) or MPRO cells
(5 × 103) [24], respectively, were added to wells of a 96
well plate containing inactivated A/PR/8/34 wild type or
A/PR/8/34 mGM-CSF~HA. Recombinant GM-CSF was
also used to establish a standard curve by which virusincorporated bioactive GM-CSF could be quantitated.
Plates were incubated at 37°C for 72 hours (BM) or 48
hours (MPRO cells). For the last 18 hours of incubation
for the cell-based bioassay, cells were pulsed with 3H-thymidine then harvested and counted using a scintillation
counter. For the viral based bioassay, Alamar Blue® (Invitrogen) was added to each well at 10% of the total volume
for the last 24 hours and Alamar Blue® reduction was
determined from the absorbance values recorded at 570
nm and 600 nm after 72 (BM) or 48 (MPRO) hours.

CTLL-2 cells (a gift from Dr. Robert Swanborg, Wayne
State University) were used as indicator cells for the bioactivity of mIL-2. Cells were maintained in complete RPMI
supplemented with recombinant mouse IL-2 (10 ng/ml).
CTLL-2 cells (5 × 103) were added to 96 well plates containing mitomycin C treated cells (wild-type or mIL-2
CYT-IVAC producer cells) or inactivated virus (A/PR/8/34
wild-type or A/PR/8/34 mIL-2~HA) as described above.
Recombinant IL-2 was also used to establish a standard
curve by which virus-incorporated bioactive IL-2 could be
quantitated. Plates were incubated at 37°C for 48 hours.
For the last 18 hours of incubation for the cell-based bio-
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assay, cells were pulsed with 3H-thymidine then harvested
and counted using a scintillation counter. For the virus
particle based bioassay, Alamar Blue® was added to each
well for the last 24 hours and absorbance was read at 570
nm and 600 nm after 48 hours.
CT.4s cells (gift from Dr. William Paul and Dr. Jane Hu-Li,
Laboratory of Immunology, National Institute of Health)
were used to determine mIL-4 bioactivity [25]. Cells were
maintained in complete RPMI supplemented with recombinant mouse IL-4 (2 ng/ml). CT.4s cells (5 × 103) were
added to 96 well plates containing mitomycin C treated
MDCK cells (wild-type or mIL-4 CYT-IVAC producer cells)
or inactivated virus (A/PR/8/34 wild-type or A/PR/8/34
mIL-4~HA) as described above. Recombinant IL-4 was
also used to establish a standard curve by which virusincorporated bioactive IL-4 could be quantitated. Plates
were incubated at 37°C for 48 hours. For the last 18 hours
of incubation for the cell-based bioassay, cells were pulsed
with 3H-thymidine, harvested and counted using a scintillation counter. For the viral based bioassay, Alamar Blue®
was added to each well for the last 24 hours and absorbance was read at 570 nm and 600 nm after 48 hours.
Standard curves for recombinant GM-CSF, IL-2 and IL-4
were deduced from the difference data of the 570 nm and
600 nm absorbance readings for each dilution of recombinant protein using Prism (GraphPad Software, Inc.).
Difference data, collected from various dilutions of GMCSF, IL-2, or IL-4-bearing CYT-IVAC preparations, was
applied to their respective standard curve for quantitation
of bioactive membrane-bound cytokine for each CYTIVAC on a per microgram basis.
Vaccination studies
Animal experiments were performed in accordance with
NIH guidelines and with approval by the Institutional
Animal Care and Use Committee of the Virginia State
University and Polytechnic Institute. Groups of 8–10
week old female Balb/c mice (NCI, Charles, River Laboratories) were immunized subcutaneously with 0.375 μg
total viral protein of β-propiolactone inactivated A/PR/8/
34 wild-type, A/PR/8/34 mGM-CSF~HA, A/PR/8/34 mIL2~HA, or A/PR/8/34 IL-4~HA diluted in PBS. PBS alone
acted as the negative vehicle control. Serum was collected
on day 21 post-vaccination by retro-orbital bleeding. Mice
were challenged with 1000 TCID50 of mouse-adapted
Influenza A/PR/8/34 (100 LD50) on day 35 post-vaccination. Weight loss and survival was monitored following
challenge.
Enzyme linked immunosorbent assay (ELISA)
Antiviral antibody levels in sera of vaccinated animals
were determined by a standard enzyme-linked immunosorbent assay using whole virus as the coating antigen.
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Briefly, Immuno Plates (Nunc) were coated with 10
hemagglutination units (HAU) of inactivated A/PR/8/34
in coating buffer (sodium bicarbonate, pH 9.6) and
blocked overnight at 4°C in PBST buffer (phosphate buffered saline with 0.05% Tween 20) supplemented with 2%
BSA. Plates were washed 3 times with wash buffer (PBS
containing 0.05% Tween 20). Serum samples, collected
on day 21 post vaccination, were added to wells of ELISA
plates and plates were incubated with shaking overnight
at 4°C. Plates were washed 3 times with PBST. Horseradish Peroxidase (HRP) conjugated secondary antibody
(anti-mouse IgG, IgG1, or IgG2a; Southern Biotech),
diluted in PBST with 2% BSA, was added and plates were
incubated with shaking for 1.5 hours at RT. Plates were
washed 3 times with wash buffer and wells were incubated with substrate (2,2'-Azino-Bis(3-Ethylbenzthiazoline-6-Sulfonic Acid; Sigma) for 30 minutes at RT,
followed by the addition of 1% SDS to stop the reaction.
Absorbance was measured at 405 nm using a plate reader
(SpectraFluor Plus, Tecan) and O.D. readings were plotted
against a standard curve to determine the amount of influenza specific antibody per milliliter of serum.
Microneutralization Assay for determination of virus
neutralizing antibody titers
Neutralizing antibody titers were determined for serum
samples collected from mice on day 21 post-vaccination
as described in the WHO Manual on Animal Influenza
Diagnosis and Surveillance [26]. Briefly, two-fold serial
dilutions of serum in PBS were incubated with 100
TCID50 of influenza A/PR/8/34 for 1 hour at room temperature. The serum/virus cocktail was added to MDCK
cells for 1 hour at 37°C. Serum/virus cocktail was
removed and cells were incubated for 3 days at 37°C in
the presence of 1.5 μg/ml TPCK-treated trypsin (Sigma).
Neutralizing titer was determined to be the reciprocal of
the last dilution of serum that protected MDCK cells from
cytopathic effect.
Quantitation of viral loads in lungs
Viral loads in the lung tissue of vaccinated mice were
determined by collecting lungs on day 4 post-challenge.
Lungs were weighed and flash frozen in DMEM with liquid nitrogen. Lung tissue was homogenized, pelleted and
supernatants were collected. Lung homogenates were
brought to equal volume with DMEM. Viral titers of lung
homogenates were determined from serial 10-fold sample
dilutions and incubation with MDCK cells for 1 hour at
37°C to allow for virus adsorption. Subsequently, cells
were washed and incubated for 3 days at 37°C in the presence of 1.5 μg/ml TPCK-treated trypsin (Sigma) and cytopathic effects were recorded. Viral loads were reported as
50% tissue culture infectious dose units (TCID50/ml) as
determined by the Reed-Muench method [27].
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Statistics
Statistical analysis using Prism software (Graphpad) was
conducted with the help of Dr. Stephen Were (statistician
for VA-MD Regional College of Veterinary Medicine).
ELISA antibody titer data was analyzed by One-way
ANOVA on normalized log transformed data using Dunnett's multiple comparison test with PR/8/34 wild-type
group as the control. Comparison of survival curves was
analyzed using Fisher's exact test.

Results
Establishment of CYT-IVAC producer cell lines for the
production of Cytokine-Bearing Influenza Vaccines (CYTIVACs)
We have previously described an in vitro cell culture platform that allows for the direct incorporation of membrane-bound forms of chicken-derived cytokines into
virus particles [22]. Preparation of these cytokine-bearing
influenza virus vaccines, or CYT-IVACs, requires that the
cytokine or immunomodulator of choice be both
anchored in the virion membrane, and efficiently packaged into virions as they are released from the infected
host cell. Further, the membrane-bound immunomodulator must retain its bioactivity. To ensure successful
membrane anchoring and virion packaging, a gene encoding for full-length cytokine (including its signal sequence)
is fused inframe to a gene segment encoding a short extracellular stalk domain, the transmembrane spanning and
the cytoplasmic tail domains of the influenza virus
hemagglutinin. Alternatively, genes encoding mature soluble forms of cytokines or chemokines can be fused
inframe to the N-terminal encoding cytoplasmic tail,
membrane-spanning and short stalk domains of the viral
neuraminidase [22].

In the present study, mouse derived IL-2, IL-4 and GMCSF were fused inframe to the C-terminal portion of the
hemagglutinin and inserted into the mammalian expression vector pcDNA3.1 (Invitrogen) under control of the
CMV promoter element; pcDNA3.1~mIL-2/HA, ~mIL-4/
HA and ~mGM-CSF/HA respectively. Following establishment of stable MDCK transfectants expressing the membrane-bound cytokines, cell surface expression was
confirmed by immunofluorescence microscopy using
cytokine-specific antibodies. As depicted in Figure 1, cell
surface expression of GM-CSF/HA, IL-2/HA or IL-4/HA
could be readily demonstrated in MDCK cells stably transfected with the respective expression constructs (Figure.
1D, E, and 1F respectively). Positive staining was absent in
vector control MDCK transfected cells using each the
cytokine specific antibodies (Figure. 1A, B, and 1C). Stable MDCK transfectants were subcloned by limiting dilution to ensure maximal surface expression of the fusion
constructs and further selected based upon i) cell surface
expression of the membrane-bound cytokines, and ii) cell
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Figure
Cell
surface
1 expression of membrane-bound immunomodulator fusion constructs
Cell surface expression of membrane-bound immunomodulator fusion constructs. Cell surface immunofluorescent
staining of wild-type MDCK cells (A, B, C) and MDCK CYT-IVAC producer cells expressing membrane-bound mouse GMCSF/HA (D), IL-2/HA (E), or IL-4/HA (F). Paraformaldehyde fixed cells were labeled using rat anti-GM-CSF (A, D), anti-IL2 (B,
E) or anti-IL4 (C, F) specific antibodies followed by Alexa Flour® 488 conjugated secondary antibody.

surface bioactivity of the specific membrane-bound
cytokines as further described below.
Membrane-bound cytokine bioactivity was determined
using specific cell-based bioassays in which MDCK transfectants, wild-type or subclones of membrane-bound
cytokine producing cells, were incubated with cytokine
specific indicator cells (Figure 2). Bioactivity or proliferation was based on the incorporation of 3H-thymidine. All
three stably transfected MDCK cell lines expressing either
mGM-CSF/HA, mIL-2/HA, or mIL-4/HA induced the proliferation of their respective indicator cell line at levels
well above background (indicator cells alone). Vector
control or wild-type MDCK cells failed to induce significant proliferation of indicator cell lines. These results confirm that the mGM-CSF, mIL-2, and mIL-4 fusion
constructs are expressed in a bioactive form on the cell
surface of our CYT-IVAC producer cells.
Viral incorporation of membrane-bound cytokines
Our goal in this study was to produce inactivated whole
virus vaccines, which exhibit immunopotentiating capacity compared to standard, unadjuvanted influenza whole
virus vaccine. In order for membrane-bound cytokines to
serve as immunopotentiating adjuvants they must first be

packaged efficiently into budding virions, and subsequently retain their bioactivity following inactivation of
the virus particles. To confirm packaging of membranebound cytokines into virions, we initially took advantage
of our work with filamentous strains of influenza virus
[28-30]. Filamentous strains allow for visualization of
virus particles budding from infected cells or of virions
released into the extracellular media using indirect
immunofluorescence microscopy techniques. To assess
whether membrane-bound cytokines at the surface of
MDCK cells were incorporated into budding virions, stable MDCK transfectants were infected with filamentous
influenza A/Udorn/72 (H3N2) virus and at 8 hours postinfection, fixed and immunostained with antibodies specific for the respective cytokines or for the viral hemagglutinin glycoprotein (HA). As demonstrated in Figure 3 (A–
D), budding filamentous virions clearly incorporated
membrane-bound GM-CSF when propagated in infected
MDCK~GM-CSF/HA expressing cells. Co-localization
(yellow fluorescence) was evident indicating that both
membrane-bound GM-CSF and full-length, virally
encoded HA were incorporated into budding viral filaments. Importantly, localization of GM-CSF/HA and full
length HA was also confirmed on virions collected from
the supernatants of infected producer cells (Figure 3D).

Page 6 of 17
(page number not for citation purposes)

Virology Journal 2009, 6:42

http://www.virologyj.com/content/6/1/42

Figure of
Membrane-bound
surface
2 MDCK CYT-IVAC
immune-modulators
producer are
cellsbioactive on the
Membrane-bound immune-modulators are bioactive
on the surface of MDCK CYT-IVAC producer cells.
Mitomycin C treated subclones (SC) or FACS sorted (sort)
CYT-IVAC producer cells expressing murine GM-CSF (A),
IL-2 (B), or IL-4 (C) or wild-type MDCK cells were co-cultured with cytokine specific indicator cells, bone marrow
(BM), CTTL-2 and CT.4s respectively. Proliferation of
cytokine responsive cell lines was measured by 3H-thymidine
incorporation. Recombinant protein was used as positive
control.

Figure 2

To further confirm cytokine incorporation into virions,
virus harvested from infected producer cells was gradientpurified and inactivated with β-propiolactone. Complete
virus inactivation was confirmed using a tissue culture
infectious dose assay, which monitors virus induced cytopathicity or production of hemagglutinating virus particles. None of the inactivated CYT-IVACs (5 μg of purified
virus) resulted in the production of hemagglutinating
virus particles or cytopathic effect in wild-type MDCK cells
over a 5 day monitoring period. Western blot analysis and
slot blot assays were performed on gradient purified CYTIVACs to further verify cytokine incorporation and to
quantitate the total amount of virus-incorporated
cytokine, respectively. In addition, the HA content of gradient purified wild-type and CYT-IVAC vaccine preparations was evaluated using slot blot and hemagglutination
assays to rule out any potential adverse effects on packaging of full-length viral HA. As depicted in Figure 3E using
western blot analysis, the presence of mGM-CSF/HA was
detected only in progeny virions harvested from A/PR/8/
34 infected mGM-CSF/HA producer MDCK cells and not
in virions collected from A/PR/8/34 infected wild-type
MDCK cells. GM-CSF was detectable in as little as 0.268
μg of total viral protein. Using standard curves derived
from slot blots of recombinant GM-CSF, IL-2 or IL-4, we
were further able to quantitate the amount of virus-incorporated cytokine for each CYT-IVAC (Table 1). The GMCSF and IL-4-bearing CYT-IVACs incorporated relatively
high levels of membrane-bound cytokines, 185 ng GMCSF and 176 ng IL-4 per μg of vaccine respectively, compared to the IL-2-bearing CYT-IVAC, only 4.924 ng IL-2
per μg of vaccine. Due to lack of a suitable HA standard for
A/PR/8/34 hemagglutinin, we were unable to precisely
quantitate the viral HA content. However, we were able to
compare the relative HA amounts based on optical density scans of western or slot blot assays in which equal
amounts of purified viral protein were loaded. Using this
approach, the HA content across vaccine preparations did
not differ significantly when equal amounts of viral protein were probed with either monoclonal or polyclonal
antibodies specific for H1 hemagglutinin (Table 1). Addi-
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Figure 3
Membrane-bound
immunomodulators are incorporated during budding and release of virions from influenza virus infected cells
Membrane-bound immunomodulators are incorporated during budding and release of virions from influenza
virus infected cells. MDCK CYT-IVAC producer cells infected with filamentous influenza virus A/Udorn/72 were stained at
8 hr post-infection with antibodies specific for mGM-CSF (A, green) and hemagglutinin (B, red). Images A and B are overlaid to
depict co-localization of mGM-CSF and full-length HA to budding viral filaments (C). Released virus particles collected from
supernatants of infected CYT-IVAC producer cells stained for GM-CSF and HA as described above (D). Western blot of gradient purified virus derived from GM-CSF/HA expressing MDCK cells or wild-type MDCK cells (E) and probed for the presence
of GM-CSF.

tionally, hemagglutination units per μg of viral protein for
wild-type and CYT-IVAC vaccines did not differ significantly, indicating comparable relative full-length HA content for wild-type and CYT-IVAC vaccines (Table 1).

ular influenza virus subtype. Additional studies in our
laboratory have further confirmed membrane-bound
cytokine incorporation using H6N2 avian strains of influenza virus for the infection (data not shown).

In these latter studies, influenza virus A/PR/8/34, a spherical particle-producing virus, was used to prepare vaccines.
Thus, incorporation of membrane-bound cytokine is neither restricted to a morphological phenotype nor a partic-

Bioacitivty of membrane-bound cytokines following viral
inactivation
Inactivated, gradient purified CYT-IVACs were subsequently analyzed by bioassay using the appropriate indi-

Table 1: Characterization of CYT-IVAC hemagglutinin and cytokine content

Vaccine

PR/8/34 w.t.
PR/8/34 GM-CSF/HA
PR/8/34 IL-2/HA
PR/8/34 IL-4/HA

HA pixel density*

HAU/μg of vaccine

Total cytokine
(ng/μg vaccine)**

Bioactive cytokine
(pg/μg vaccine)***

5835.4
6407.9
5562.9
6090.4

16
16
32
32

NA
185 ± 21
4.92 ± 0.3
176 ± 24

NA
87.3
411
456

* Pixel density of HA specific chemiluminescent signal following equal loading of total viral protein
** Quantitation of virus-incorporated cytokine on protein level based on standard curve of recombinant cytokine (ng of cytokine per ug of vaccine)
*** Quantitation of virus-incorporated cytokine on bioactive level based on standard curve of recombinant cytokine (pg of cytokine per ug of
vaccine)

Page 8 of 17
(page number not for citation purposes)

Virology Journal 2009, 6:42

http://www.virologyj.com/content/6/1/42

cator cells. Wild-type inactivated virus harvested from
vector control MDCK cells was used as a negative control
and proliferation was monitored by either 3H-thymidine
incorporation or reduction of Alamar Blue®. Alamar Blue®
is a safe, non-radioactive alternative to3H-thymidine and
it has been proven to be as sensitive and reproducible, in
proliferation assays, as3H-thymidine [31]. As depicted in
Figure 4, CYT-IVACs bearing mGM-CSF/HA, mIL-2/HA,
and mIL-4/HA, all retained their bioactivity following βpropiolactone inactivation inducing significant proliferation of their respective indicator cell lines compared to
wild-type inactivated virus. In addition to the above-mentioned quantitation of virus-incorporated cytokine by slot
blot assays, we thought it necessary to quantitate the biologically active membrane-bound cytokine to better indicate the dose of cytokine delivered during vaccination.
Despite the relatively low level of virus-incorporated IL-2
compared to IL-4, the amount of biologically active IL-2
and IL-4 present in the respective CYT-IVACs was comparable at 0.411 ng IL-2 and 0.456 ng IL-4 perμg of vaccine,
respectively (Table 1). In contrast, the amount of bioactive membrane-bound GM-CSF for the GM-CSF CYTIVAC was considerably lower (87.3 pg perμg of vaccine)
despite the relatively high level of virus-incorporated GMCSF as determined by the slot blot assay (Table 1).
To verify that positive bioassays were due to the presence
of bioactive cytokines we included non-specific CYTIVACs and cytokine-neutralizing antibodies in our evaluation. The IL-2 and IL-4 bioassays were shown to be specific for their respective cytokines as the IL-4 CYT-IVAC
failed to induce significant proliferation of IL-2 dependent CTLL-2 cells (Figure 5A) and similarly, the IL-2 CYTIVAC failed to induce the proliferation of IL-4 dependent
CT.4s cells (Figure 5B). Furthermore, the addition of neutralizing anti-IL-2 antibodies to the culture media reduced
proliferation of IL-2 CYT-IVAC stimulated CTLL-2 cells in
a dose dependent manner (Figure 5C).
CYT-IVACs enhance serum anti-viral antibodies and skew
immune response toward Th1 mediated immunity
To evaluate the adjuvant potential of our CYT-IVACs, we
vaccinated groups of Balb/c mice with CYT-IVACs or wildtype vaccine administered subcutaneously (s.c.). In pilot
studies, we determined the dose of inactivated, wild-type
A/PR/8/34 vaccine that results in seroconversion and protection against lethal challenge in 20% of mice, the 20%
mouse protective dose (MPD20). This dose (0.375 μg) was
chosen in order to evaluate subtle immunopotentiating
responses induced by our CYT-IVACs. Importantly, we
chose not to include a boosting dose so that we could
determine whether single dose vaccination with CYTIVACs offered more protection than wild-type vaccine. It
should also be noted that no adjuvant other than the particulate matter of the vaccine itself or the incorporated

Figureviral
Membrane-bound
lowing
4 inactivation
immunomodulators retain bioactivity folMembrane-bound immunomodulators retain bioactivity following viral inactivation. Cytokine specific indicator cell lines (bone marrow cells, BM; CTTL-2; or CT.4s)
were incubated with decreasing concentrations of β-propiolactone inactivated wild-type vaccine or GM-CSF CYT-IVAC
(A), IL-2 CYT-IVAC (B) or IL-4 CYT-IVAC (C). Proliferation
was determined by Alamar Blue® reduction. Recombinant
protein was used as the positive control.
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Figure
Proliferation
ent
on the
5 respective
induced by
membrane-bound
CYT-IVACs is specific
cytokine
and dependProliferation induced by CYT-IVACs is specific and
dependent on the respective membrane-bound
cytokine. Proliferation of cytokine responsive cell lines
CTLL-2 (A) and CT.4s (B) was measured following incubation with β-propiolactone inactivated mIL-2 or mIL-4 bearing
CYT-IVACs. IL-2 CYT-IVAC induced proliferation of CTLL-2
cells was inhibited in a dose dependent manner with antimIL-2 neutralizing antibodies (C). Recombinant protein was
used as a positive control.

cytokine was administered. Blood was collected from
mice at day 21 post-vaccination and sera were evaluated
by ELISA against whole viral antigens to determine elicited anti-viral antibody titers. Following subcutaneous
vaccination, significant increases in influenza specific
total IgG were found in mice vaccinated with the mIL-2
bearing CYT-IVAC compared to wild-type vaccinated mice
(Figure 6). While IgG levels were elevated in mice vaccinated with the mIL-4 bearing CYT-IVAC, these levels were
not significantly higher that wild-type vaccinated mice.
Interestingly, we found influenza specific IgG levels in
mice vaccinated with the mGM-CSF bearing CYT-IVAC to
be much lower than the wild-type vaccinated mice.
To further characterize the immune response elicited by
CYT-IVACs we determined the influenza specific IgG1 and
IgG2a levels in the serum by ELISA. It is well established
that elevated IgG1 isotype levels, compared to IgG2a, is
indicative of a Th2 mediated immune response whereas
high IgG2a levels is indicative of a predominately Th1-type
response. Mice vaccinated with either the mIL-2 CYTIVAC or the mIL-4 CYT-IVAC had significantly higher
IgG2a titers compared to wild-type vaccinated mice (Figure
7). Although significantly higher IgG1 titers were detected
in IL-2 CYT-IVAC vaccinated mice compared to wild-type
vaccinated mice, the IgG2a isotype remained the predominant influenza specific isotype detected in serum samples
collected from mIL-2 or mIL-4 CYT-IVAC vaccinated mice,
indicating a skewing towards a Th1 immune response.

Figure 5

It is important to note that there was no direct correlation
between elevated antibody titers and protection when
evaluated on a mouse-by-mouse basis. That is, mice with
high influenza specific antibody titers were not necessarily
protected following lethal challenge and several mice
from the IL-2 and IL-4 CYT-IVAC groups, which displayed
low seroconversion titers survived lethal challenge. We
were unable to detect neutralizing antibodies in any of the
serum samples, however, neutralizing immune responses
were clearly evoked upon challenge as viral loads were significantly reduced in the IL-2 and IL-4 CYT-IVAC vaccinated animals at day 4 post-challenge (see Figure 8). It is
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Figure 6 influenza vaccines bearing membrane-bound immunomodulators enhance serum anti-viral antibody titers
Inactivated
Inactivated influenza vaccines bearing membrane-bound immunomodulators enhance serum anti-viral antibody titers. Balb/c mice were vaccinated subcutaneously with 0.375 μg of A/PR/8/34 wild-type (n = 20) or A/PR/8/34 bearing
membrane-bound GM-CSF (n = 10), IL-2 (n = 19), and IL-4 (n = 20). PBS served as negative vehicle control. Serum was collected on day 21 post-vaccination and antibody titers for influenza virus specific IgG and isotypes IgG1 (Th2) and IgG2a (Th1)
were determined by ELISA. Data is displayed as the geometric mean titer in ng/ml for each group. (* p < 0.05 compared to PR/
8/34 w.t., ** p < 0.01 compared to PR/8/34 w.t.)

therefore possible that our microneutralization assay was
not sensitive enough to detect the low levels of neutralizing antibody induced by the single low dose of vaccine
administered.
Vaccination with CYT-IVACs results in enhanced
protection against lethal influenza virus challenge
The most compelling evidence supporting the immunostimulatory or immunomodulatory properties of our CYTIVACs was the protection against lethal challenge. Here

single dose, vaccinated mice were challenged on day 35
post vaccination with a lethal dose of mouse-adapted
influenza A/PR/8/34 (100 LD50). Weight loss and survival
were monitored following challenge. Weight loss in mice
vaccinated subcutaneously with wild-type vaccine or
mGM-CSF bearing CYT-IVAC closely mimicked that of
PBS (sham) inoculated mice (Figure 7A). Sudden
increases in percent weight loss in these groups between
days 6 and 8 can be explained by a combination of recovering weight of remaining mice and loss of mice due to

Page 11 of 17
(page number not for citation purposes)

Virology Journal 2009, 6:42

http://www.virologyj.com/content/6/1/42

Figure
Inactivated
7 influenza vaccines bearing membrane-bound immunomodulators protect mice against lethal challenge
Inactivated influenza vaccines bearing membrane-bound immunomodulators protect mice against lethal challenge. Balb/c mice were vaccinated subcutaneously with 0.375 μg of inactivated wild-type vaccine (n = 20) or CYT-IVACs
bearing membrane-bound GM-CSF (n = 10), IL-2 (n = 19), or IL-4 (n = 20) vaccine preparations. Mice were then challenged
with 100 LD50 of mouse-adapted A/PR/8/34 on day 35 post-vaccination. PBS served as negative vehicle control. Percent weight
change (A) and survival (B) were monitored over time. (* p < 0.05 compared to PR/8/34 w.t., *** p < 0.001 compared to PR/8/
34 w.t.)
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CYT-IVAC
Figure 8 vaccination significantly reduces viral loads in lung tissue following lethal challenge
CYT-IVAC vaccination significantly reduces viral loads in lung tissue following lethal challenge. Mice vaccinated
with either wild-type vaccine or CYT-IVACs challenged on day 35 post-vaccination with 100 LD50 of mouse-adapted A/PR/8/
34. Mice were sacrificed on day 4 post-challenge and viral loads from homogenized lung tissue (n = 3) were determined by tissue culture infectious dose assay. Data is expressed as TCID50 per gram of lung tissue. (* p < 0.05 compared to PR/8/34 w.t.)
death; albeit mostly due to the latter. Only 20% of mice
vaccinated subcutaneously with wild-type vaccine and
10% of mGM-CSF CYT-IVAC vaccinated mice were protected against lethal homotypic challenge (Figure 7B).
Mice vaccinated with mIL-2 or mIL-4 bearing CYT-IVAC
exhibited reduced and delayed weight loss compared to
mice vaccinated with wild-type vaccine. Over 50% (p <
0.05) of mice vaccinated with mIL-2 bearing CYT-IVAC
and 75% (p < 0.001) of mIL-4 CYT-IVAC vaccinated mice
survived lethal challenge (Figure 7B) and those mice that
succumbed to infection took considerably longer to do so.
CYT-IVAC vaccination resulted in reduced viral loads in
lungs of infected mice
In addition to evaluating protection from lethal challenge
we compared viral loads in lungs of mice vaccinated with

CYT-IVACs or wild-type vaccine following challenge on
day 35 post vaccination. Lungs were harvested from 3
mice per vaccine group on day 4 post-challenge and viral
loads of lung homogenates were determined for each
mouse. We chose to omit the mGM-CSF CYT-IVAC from
this study because previously recorded results indicated
no adjuvant effect for this CYT-IVAC, when administered
subcutaneously. Viral titers in the lungs of mice vaccinated with either the mIL-2 or mIL-4 CYT-IVAC were a full
log lower compared to mice vaccinated with the wild-type
vaccine (Figure 8), further confirming the enhanced protective efficacy afforded by membrane-bound cytokines
on the virus particles.
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Discussion
In the present study we describe a novel approach to
immunopotentiate the anti-viral, protective response
induced by whole virus inactivated influenza vaccines
without the need for additional adjuvants or boosting
doses of vaccine. Not only were our cytokine-bearing
influenza vaccines (CYT-IVACs) more efficacious than
non-adjuvanted whole virus vaccine, but they skewed the
elicited humoral response towards a Th1 mediated
humoral immune response. Previously, we demonstrated
feasibility of this platform for production of avian influenza vaccines bearing a membrane-bound form of
chicken-derived IL-2 and GM-CSF [22]. CYT-IVAC-bearing chIL-2 significantly boosted antiviral antibody titers in
vaccinated chicks compared to unadjuvanted vaccine.
Here, we have extended these studies and were able to successfully develop a platform upon which membranebound forms of mammalian-derived immunomodulatory proteins such as mouse IL-2, IL-4, or GM-CSF can efficiently be incorporated into budding virus particles.
Importantly, we confirmed that bioactivity was retained
following inactivation of the virus with formaldehyde
(data not shown) or β-propiolactone, two virus inactivating agents commonly used during the formulation of current influenza vaccines [32]. Further, we were able to
demonstrate that the intrinsic proliferative-inducing activity associated with each individual CYT-IVACs was specific for the incorporated membrane-bound cytokine
(Figure 5). This suggests that it is not simply the inclusion
of the fusion protein itself that conveys immune stimulating properties, but the demonstrated bioactivity of the
incorporated cytokine. It should also be noted that longterm storage (> 12 months at 4°C) did not result in any
loss of cytokine specific bioactivity associated with the
inactivated CYT-IVACs. In our hands, CYT-IVACs are stable and remain bioactive even following freeze/thaw
when stored at -80°C.
Viral incorporation of membrane-bound cytokines is
achieved through interactions between the viral matrix
protein and cytoplasmic tail domains of the cytokine
fusion construct, which is the same interaction used to
incorporate viral hemagglutinin. Thus, there was the possibility that this platform would result in significant loss
of full-length viral HA in our CYT-IVACs. Although we
were unable to determine exact full-length HA protein levels, for lack of a purified standard, optical density measurements were highly similar among CYT-IVACs using
HA1 (H1) specific antibodies in slot blot assays. This suggests that total HA levels were not markedly reduced in the
CYT-IVACs compared to wild-type vaccine. In addition,
hemagglutination units (HAU/μg total viral protein) of
CYT-IVAC and wild-type vaccines did not differ significantly (Table 1). Since we did not fully understand how
anchoring the cytokine to the virus particle may affect its
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full biological capacity, we quantitated both cytokine protein levels and specific bioactivity associated with individual CYT-IVAC formulations. There was considerable
variation in the levels of incorporated cytokine based on
protein content as well as associated bioactivity. For
example, membrane-bound GM-CSF was incorporated at
relatively high levels yet was poorly bioactive. Both IL-2
and IL-4 CYT-IVACs exhibited similar cytokine specific
bioactivity, yet had variable amounts of incorporated
cytokines. Of note, membrane-bound cytokine incorporation was relatively consistent across several independent
vaccine preparations based on associated bioactivity per
μg of viral protein (data not shown). This suggests that the
observed variation in incorporation is specific for a given
fusion construct and not due to variation in growth propagation of the virus in cell culture. The observed variability may partially explain why the GM-CSF CYT-IVAC, with
low associated bioactive GM-CSF, did not provide better
protection that the wild-type vaccine. Future formulations
in which the GM-CSF molecule is extended further out
from the virus particle may help enhance its bioactivity.
Clearly, the amount of incorporated cytokine necessary to
achieve an immunopotentiating effect will likely be
cytokine specific and will require additional testing to
optimize in vivo immunomodulatory effective dose.
Our approach of anchoring immunostimulators directly
to the inactivated virus particle was designed to augment
responses to current trivalent inactivated influenza vaccine platforms, which include three formulations, whole
virus, split, or subunit vaccines with whole virus vaccines
being the most immunogenic [33-36]. TIVs are generally
well tolerated with few, if any, adverse reactions reported
[37]. Adverse reactions have been reported in children
vaccinated with whole virus formulations and they are
generally administered split or subunit vaccines [32,38];
however, CYT-IVACs might reduce side effects of whole
virus formulations if they permit the use of lower antigenic doses. Immunity induced by TIVs is dominated by
humoral immunity, predominantly influenza specific
serum IgG1 [39-42]. Our CYT-IVACs bearing IL-2 and IL-4
were both able to induce a more balanced response as evident by the higher levels of antiviral IgG1 and IgG2a antibodies compared to wild-type unadjuvanted virus
vaccine. Though we did not directly assess cellular
immune responses to our CYT-IVACs, isotype switching
from IgG1 to IgG2a is known to be stimulated during Th1type immune responses, and has been implicated in
increased clearance of influenza infections following
influenza vaccination [43-50]. Interestingly, the conventional immunological function of IL-4 is to stimulate Th2
type immune effectors and to suppress Th1 immunity.
However, the IL-4 bearing CYT-IVAC, which induced elevated IgG2a antibody titers, appears to be able to polarize
immune effectors in a different manner than that
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described for soluble IL-4 [51-54]. Other groups have
reported that IL-4 in a membrane-bound form and in a
highly localized environment can induce IL-12 production, a potent Th1 inducer, in APCs [55-58]. As noted,
results obtained with the GM-CSF bearing CYT-IVAC were
less conclusive and may be due in part to the reduced bioactivity of membrane-bound GM-CSF incorporated into
virus particles. Large doses of GM-CSF can have an inhibitory effect on effector T cell function or lead to activation
and expansion of myeloid suppressor cells [59,60]. This
will require further clarification and additional studies.
Efficacy of TIVs in elderly and immunocompromised
individuals is poor (30–70%) due in part to decreased
immune function in these individuals that results in lower
antibody titers following vaccination [32]. The inability of
TIVs to effectively protect the elderly and to induce crossprotection has led to investigation of adjuvants such as
Microfluidized Emulsion 59 (MF59), aluminum or toxin
based adjuvants, and FLU-ISCOMs that aid in enhancing
the immune response to inactivated influenza vaccines
[7,8,61-69]. Our CYT-IVACs may provide the necessary
adjuvant-like activity to stimulate protective responses in
the elderly and this is currently being evaluated in our laboratory using an aged mouse model.
A wide range of applications exists for our cytokine-bearing viral vaccine technology. It is adaptable to a variety of
species including avian, swine, canine, and equine by simply introducing species-specific immunomodulators.
Likewise, human-specific immunomodulators can be
incorporated in the platform for production of human
specific viral vaccines. Importantly, depending on the
location of the bioactive domains, immunomodulators
can be presented either as type I or II membrane-bound
molecules on the virus particle. This also serves to overcome potential steric hindrances that may occur during
cytokine folding and/or presentation. In our laboratory,
we have been able to incorporate these membrane-bound
immunomodulators in H3N2, H1N1 as well as H6N2
(data not presented) influenza virus strains using the
same CYT-IVAC producer cell line. Thus, vaccines against
newly emerging influenza strains can be readily produced
using our CYT-IVAC producer cell lines. It should also be
noted, that this approach is amenable to virtually any
enveloped virus, requiring only virus specific adaptation
of the membrane-anchoring domain to ensure incorporation during the budding process. This approach is also
amenable for inclusion of membrane-bound flagellin
into baculovirus-derived influenza virus-like particles
[70]. Our study provides independent evidence supporting the versatility and practicality of membrane-bound
immunomodulators as effective viral vaccine adjuvants.
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Conclusion
We have demonstrated both the feasibility of viral incorporation of membrane-bound immunomodulators by
influenza viruses and the enhanced efficacy of our CYTIVACs compared to conventional, non-adjuvanted influenza virus vaccines. Superior immunogenicity of CYTIVACs was manifested as elevated influenza specific antibodies, particularly IgG2a isotypes implicating Th1 mediated immunity. Enhanced protection from infection was
also demonstrated for IL-2 and IL-4 CYT-IVAC vaccinated
mice further illustrating the adjuvant effect of membranebound IL-2 and IL-4. The adjuvant or immune stimulating
properties of CYT-IVACs makes them attractive candidates
for inducing a more robust and protective immune
response in the elderly and immunocompromised individuals where immune responses are waning or compromised.
Further,
the
membrane-bound
immunomodulators may be helpful in either augmenting
the immunogenicity of influenza vaccines that require
large antigen doses to confer protection or in reducing the
dose required for protection. This could significantly
increase vaccine availability targeting low immunogenic
strains such as H5N1. Current studies in our lab encompassing additional immunostimulatory molecules, the
intranasal route of vaccine delivery, efficacy in the aged
mouse model and other enveloped virus platforms will
help expand the utility and efficacy of the CYT-IVAC
approach.
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